Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease
Section snippets
Acknowledgements
This work was supported by the University of Birmingham and the Birmingham and Solihull NHS Mental Health Trust. Dr Yong Zhang was a visiting fellow from the China Scholarship Council.
References (18)
- et al.
Association between an interleukin-6 promoter and 3′ flanking region haplotype and reduced Alzheimer's disease risk in a German population
Neurosci. Lett.
(2000) - et al.
Genetic polymorphisms in the cathepsin D and interleukin 6 genes and the risk for Alzheimer's disease
Neurosci. Lett.
(2000) - et al.
Pathological relationships between microglial cell activity and tau and amyloid β protein in patients with Alzheimer's disease
Neurosci. Lett.
(2002) - et al.
Visualization of a β42(43) and a β40 in senile plaques with end-specific Aβ monoclonals – evidence that an initially deposited species is Aβ42(43)
Neuron
(1994) - et al.
Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain
Neurobiol. Aging
(2003) - et al.
Glial cytokines in Alzheimer's disease – review and pathogenic implications
Hum. Pathol.
(1995) - et al.
Genetics of interleukin 6: implications for Alzheimer's disease
Neurobiol. Aging
(2001) - et al.
Sib pair linkage and association studies between bone mineral density and interleukin-6 gene locus
Bone
(2000) - et al.
Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation
J. Biol. Chem.
(2000)
Cited by (37)
The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients
2021, Biochimica et Biophysica Acta - Reviews on CancerCitation Excerpt :Single nucleotide polymorphisms (SNPs, −572 G/C, −597 G/A, −1363 G/T, and − 2954 G/C) are also considered to play an important role in IL-6 gene expression. Moreover, the polymorphism -174G/C in the IL-6 promoter is associated with several diseases, e.g., coronary heart disease and Alzheimer's disease [7–10]. The posttranscriptional regulation of IL-6 promotes mRNA degradation or inhibits protein translation, which is mediated by regulatory proteins (e.g., tristetraprolin, ARE/poly-(U) binding degradation factor 1, ZCCHC11) that bind to cis-acting elements in the 3’-UTRs of mRNA transcripts [11].
Genetic polymorphisms of interleukin genes and the risk of Alzheimer's disease: An update meta-analysis
2016, Meta GeneCitation Excerpt :These findings suggested ILs to be important factors in AD pathogenesis. Several epidemiological studies have investigated the association between genetic polymorphisms of IL genes and the risk of AD, including − 889C > T (rs1800587) in IL-1α, − 511C > T (rs16944) in IL-1β, − 174C > G (rs1800795) in IL-6 and − 1082G > A (rs1800896) in IL-10 (Bagli et al., 2000; Bhojak et al., 2000; Du et al., 2000; Grimaldi et al., 2000; Minster et al., 2000; Nicoll et al., 2000; Rebeck, 2000; Ki et al., 2001; Prince et al., 2001; Combarros et al., 2002; Fidani et al., 2002; Green et al., 2002; Hedley et al., 2002; Mattila et al., 2002; Pirskanen et al., 2002; Pola et al., 2002; Shibata et al., 2002; Clarimon et al., 2003; Depboylu et al., 2003; Faltraco et al., 2003; Kuo et al., 2003; Licastro et al., 2003; Lio et al., 2003; Ma et al., 2003; McCarron et al., 2003; Sciacca et al., 2003; Tsai et al., 2003; Arosio et al., 2004; Capurso et al., 2004; Depboylu et al., 2004; Hayes et al., 2004; Li et al., 2004; McCulley et al., 2004; Nishimura et al., 2004; Scassellati et al., 2004; Zhang et al., 2004; Koivisto et al., 2005; Ma et al., 2005; Seripa et al., 2005; Wang et al., 2005; Culpan et al., 2006; Ramos et al., 2006; Ravaglia et al., 2006; Zhou et al., 2006; Bagnoli et al., 2007; Wang et al., 2007; Combarros et al., 2008; Deniz-Naranjo et al., 2008; Paradowski et al., 2008; Dursun et al., 2009; Hu et al., 2009; Klimkowicz-Mrowiec et al., 2009; Serretti et al., 2009; Vural et al., 2009; Capurso et al., 2010; Combarros et al., 2010; Klimkowicz-Mrowiec et al., 2010; Ribizzi et al., 2010; Shawkatova et al., 2010; Cousin et al., 2011; Vendramini et al., 2011; Heun et al., 2012; Mansoori et al., 2012; Payao et al., 2012; Moraes et al., 2013; Rasmussen et al., 2013; Torres et al., 2013; Flex et al., 2014; Kang et al., 2014; Tian et al., 2015; Toral-Rios et al., 2015). However, these epidemiological studies have reported inconsistent results.
Association study of the BIN1 and IL-6 genes on Alzheimer's disease
2016, Neuroscience LettersCitation Excerpt :From 22 case-control studies of the −174 G/C IL-6 risk association for AD listed on AlzGene [20] for Caucasians, 12 showed positive associations, 9 showed negative associations and 1 indicated a trend for LOAD. Furthermore, the majority of studies in European individuals did not find significant association for this polymorphism with AD [28–34]. Studies in Brazilian populations with the −174 G/C IL-6 polymorphism are scarce and not consensual.
Interleukin-6 -174G/C polymorphism and the risk of Alzheimer's disease in Caucasians: A meta-analysis
2011, Neuroscience LettersInterleukin 6-174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease
2010, Progress in Neuro-Psychopharmacology and Biological PsychiatryInterleukin-6 gene -174 C/G and apolipoprotein E gene polymorphisms and the risk of Alzheimer disease in a Polish population
2010, Neurologia i Neurochirurgia PolskaCitation Excerpt :In other studies on Italian populations the IL-6 C allele increased the risk of AD [12,14], the C/C genotype increased the risk of AD in women [17], and the G/G genotype was lower in AD than in healthy controls [15]. However, other studies did not find an association between the IL-6 polymorphism and AD [14, 20–28]. Differences in study design and the geographical variations of IL-6 frequency may in part explain the different patterns of association between this polymorphism and AD in various studies.